rb 6145 has been researched along with EHS Tumor in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (88.89) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, GE; Cole, S; Fielden, EM; Naylor, MA; O'Neill, P; Stephens, MA; Stratford, IJ; Threadgill, MD; Webb, P | 1 |
| Fitzmaurice, RJ; Lunt, SJ; Stratford, IJ; Telfer, BA; Williams, KJ | 1 |
| Siemann, DW | 1 |
| Adams, GE; Butler, SA; Cole, SM; Sansom, JM; Stratford, IJ; Szabo, C; Thiemermann, C; Wood, PJ | 1 |
| Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ | 1 |
| Arnold, S; Chaplin, DJ; Collingridge, D; Hill, SA; Horsman, MR; Overgaard, J; Radacic, M; Wood, PJ | 1 |
| Adams, GE; Cole, S; Elliott, W; Fielden, EM; Leopold, W; Sebolt-Leopold, J; Stratford, IJ; Suto, M | 1 |
| Binger, M; Workman, P | 1 |
| Adams, GE; Bowler, J; Cole, S; Lorimore, SA; Nolan, J; Stratford, IJ; Wright, EG | 1 |
9 other study(ies) available for rb 6145 and EHS Tumor
| Article | Year |
|---|---|
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Mice; Nitro Compounds; Radiation-Sensitizing Agents; Sarcoma, Experimental; Structure-Activity Relationship; Thiophenes | 1991 |
Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Female; Hypoxia; Mice; Mice, Inbred C3H; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Treatment Outcome; Triazines | 2005 |
Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872.
Topics: Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Lomustine; Mice; Nitroimidazoles; Prodrugs; Sarcoma, Experimental; Stereoisomerism; Tumor Cells, Cultured | 1995 |
Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine.
Topics: Animals; Arginine; Carcinoma; Cell Hypoxia; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Energy Metabolism; Female; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C3H; Nitroarginine; Nitroimidazoles; Phosphates; Prodrugs; Sarcoma, Experimental | 1994 |
Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Topics: Animals; Antineoplastic Agents; Mice; Mice, Inbred C3H; Misonidazole; Mitomycin; Nitroimidazoles; Photochemotherapy; Sarcoma, Experimental | 1994 |
Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Female; Hyperthermia, Induced; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred CBA; Nitroarginine; Nitroimidazoles; Regional Blood Flow; Sarcoma, Experimental | 1996 |
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Topics: Animals; Cell Hypoxia; Combined Modality Therapy; Drug Evaluation; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1992 |
Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Half-Life; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Prodrugs; Sarcoma, Experimental | 1991 |
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Topics: Administration, Oral; Animals; Combined Modality Therapy; Injections, Intraperitoneal; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1991 |